16258-05-2 Usage
Description
2-AMINOHEX-5-ENOIC ACID, also known as Homoallylglycine, is a glycine derivative characterized by its yellow solid appearance. It is known for its translational activity in Escherichia coli, which makes it a significant compound in the field of microbiology and biochemistry.
Uses
Used in Pharmaceutical Industry:
2-AMINOHEX-5-ENOIC ACID is used as an active pharmaceutical ingredient for its translational activity in Escherichia coli. This property makes it a valuable compound in the development of new drugs and therapies targeting bacterial infections and related conditions.
Used in Research and Development:
In the field of research and development, 2-AMINOHEX-5-ENOIC ACID serves as a key component in studying the mechanisms of translation in bacteria. Its use in laboratory settings contributes to the advancement of knowledge in microbiology, molecular biology, and the development of novel antibiotics and treatments for bacterial diseases.
Used in Chemical Synthesis:
As a glycine derivative, 2-AMINOHEX-5-ENOIC ACID is also utilized as an intermediate in the synthesis of various chemical compounds. Its unique structure allows for its use in creating new molecules with potential applications in different industries, including pharmaceuticals, agriculture, and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 16258-05-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,2,5 and 8 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 16258-05:
(7*1)+(6*6)+(5*2)+(4*5)+(3*8)+(2*0)+(1*5)=102
102 % 10 = 2
So 16258-05-2 is a valid CAS Registry Number.
16258-05-2Relevant articles and documents
Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
-
, (2008/06/13)
Methods for producing modified polypeptides containing amino acid analogues are disclosed, as well as compositions comprising purified dihydrofolate reductase polypeptides, produced by the methods of the invention. In certain aspects, methionine residues of the compositions are replaced with homoallyglycine, homoproparglycine, norvaline, norleucine, cis-crotyiglycine, trans-crotylglycine, 2-aminoheptanoic acid, 2-butynyiglycine and allyglycine.
